Comments on: Novartis Drug Cuts Risk Of Breast Cancer Return http://www.pharmalot.com/2008/05/novartis-drug-cuts-risk-of-breast-cancer-return/ News, Comment and Conversation Fri, 10 Feb 2012 20:53:34 +0000 http://wordpress.org/?v=2.6.2 By: Lilli http://www.pharmalot.com/2008/05/novartis-drug-cuts-risk-of-breast-cancer-return/#comment-357700 Lilli Sun, 01 Jun 2008 20:32:58 +0000 http://www.pharmalot.com/?p=13884#comment-357700 My family experiences of The Robert Wood Johnson Cancer Center in New Brunswick, NJ is not favorable. Perhaps, many have been helped, but the care and and conditions that they treat senior citizens is not to be admired. As for medications we must treat patients as individuals---not as a clinical statistic. Some information about Eric Winner, Md. Eric P. Winer, MD, Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Director, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, Massachusetts Disclosure: Eric P. Winer, MD, has disclosed that he has received grants for clinical research from Aventis, Genentech, and GlaxoSmithKline and has served as an advisor or consultant to Genentech and GlaxoSmithKline. My family experiences of The Robert Wood Johnson Cancer Center in New Brunswick, NJ is not favorable. Perhaps, many have been helped, but the care and and conditions that they treat senior citizens is not to be admired. As for medications we must treat patients as individuals—not as a clinical statistic.

Some information about Eric Winner, Md.

Eric P. Winer, MD, Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts; Director, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, Massachusetts
Disclosure: Eric P. Winer, MD, has disclosed that he has received grants for clinical research from Aventis, Genentech, and GlaxoSmithKline and has served as an advisor or consultant to Genentech and GlaxoSmithKline.

]]>